Business
ARIUS to Present at the International Congress
ARIUS to Present at the International Congress.
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\n\nTORONTO, Aug. 18 /CNW/ - ARIUS Research Inc. (\"ARIUS\") (TSX: ARI) today\nannounced that Dr. David Young, President and CSO of ARIUS, will give a talk\non ARIUS' \"FunctionFIRST(TM) Antibody Technology\" at the International\nCongress on Monoclonal Antibodies in Cancer in Washington, DC on August 19,\n2006 at 4:40 p.m. local time.\nDr. Young has pioneered an approach to the discovery of antibody drugs to\ntreat cancer through ARIUS' unique FunctionFIRST(TM) platform. ARIUS uses\ntumor tissues from patients to generate antibodies then uses functional\nscreening to select the ones that attack and kill cancer cells or prevent them\nfrom growing. Dr. Young's presentation will review the various scientific\nmethods for antibody discovery and provide a description and discussion of the\nbenefits of the FunctionFIRST(TM) approach. His talk will also include a\nreview of the novel antibodies and targets produced by the ARIUS platform.\nARIUS has entered into collaborations with other biopharma companies such\nas PDL Biopharma Inc., Takeda Pharmaceutical Company Limited and Oxford\nBioMedica PLC based on the FunctionFIRST(TM) platform. ARIUS has also\nout-licensed one of its lead programs to Genentech, Inc and is pursuing\nadditional partnerships to move the next cohort of antibody treatments into\nhuman clinical trials.\n\nAbout ARIUS\n\nARIUS is a biotechnology company dedicated to personalizing cancer\ntherapy through the discovery and development of novel anticancer monoclonal\nantibodies (MAbs). Established in 1999, ARIUS has built a proprietary\ntechnology platform, FunctionFIRST(TM), that rapidly identifies powerful MAbs\ntargeting a variety of cancer indications. This antibody generation engine has\nenabled ARIUS to assemble a growing pipeline, which is used for commercial\ncollaborations and in-house development. ARIUS has ongoing partnerships with\nkey biotechnology and drug development companies. ARIUS is listed on the TSX\nunder the symbol \"ARI\".\n\nForward-Looking Statement\n\nCertain statements in this news release constitute \"forward-looking\nstatements\" within the meaning of the Private Securities Litigation Reform Act\nof 1995, which involve known and unknown risks, uncertainties and other\nfactors that may cause our actual results to be materially different from any\nfuture results, performance or achieve...